However, concerns of adverse neurocognitive effects of PCSK9 inhibition have been raised from a network meta‐analysis of RCTs of PCSK9 inhibitors in middle‐aged and older individuals.42 Another MR analysis has also suggested potentially detrimental effects of lower PCSK9 function on cognitive ability in a cohort of participants aged 38 to 73 years.43 A further consideration is whether PCSK9 inhibition might harm the cerebral vasculature (independently of effects on atherosclerosis). This evidence concerns the gene PCSK9 and atherosclerosis.